Search Results
May 11, 2026, 06:08 ET cultivate(MD) Focus Fund Announces Initial Capital Deployments
recent FDA clearance is a meaningful win for many patients and their physicians who need a better option for diagnosing and excising small peripheral lung masses, and we're proud to co‑lead their Series B. Virtual Incision, SpinTech MRI, and SentiAR are similarly executing on meaningful clinical milestones.
More news about: cultivate(MD)
May 11, 2026, 06:00 ET Partner Therapeutics Announces FDA Approval of BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner's National Priority Voucher
for Grade 4 or life-threatening IRR or hypersensitivity/anaphylaxis reactions.Interstitial Lung Disease/PneumonitisBIZENGRI can cause serious and life-threatening interstitial lung disease (ILD)/pneumonitis.In the eNRGy study, ILD/pneumonitis occurred in 2 (1.1%) patients
More news about: Partner Therapeutics, Inc.
May 10, 2026, 20:00 ET Innovent Announces IBI363 (PD-1/IL-2α-bias Bispecific Fusion Protein) Received Third NMPA Breakthrough Therapy Designation for MSS/pMMR Metastatic Colorectal Cancer
IBI363 has received two BTDs from China's NMPA CDE and two Fast Track Designations (FTDs) from the U.S. FDA, covering indications in non-small cell lung cancer and melanoma. The latest BTD further validates IBI363's potential in addressing immunotherapy resistance and cold tumor challenges which represent
More news about: Innovent Biologics
May 10, 2026, 09:00 ET Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP
Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1(st) line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." In addition,
More news about: THE ROSEN LAW FIRM, P. A.
May 08, 2026, 12:36 ET This Mother's Day, ProCure Proton Therapy Center Urges Women to Give Themselves the Gift of Screening
opened in March 2012 as the tri-state region's first proton therapy facility, treating a range of cancers including diseases of the prostate, breast, lung, brain, head and neck, and gastrointestinal system, as well as sarcomas and many pediatric cases. Using the most advanced radiation treatment available,
More news about: ProCure Proton Therapy Center
May 08, 2026, 07:30 ET Alpha Releases First Quarter 2026 Financial Results
9,841Workers' compensation and black lung obligations189,527
More news about: ALPHA METALLURGICAL RESOURCES, INC.
May 08, 2026, 06:47 ET 蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗一線治療PD-L1陽性NSCLC的sNDA獲NMPA受理
("該申請")已獲中國國家藥品監督管理局(NMPA)藥品審評中心(CDE)受理，用於聯合默沙東[1]的抗PD-1單抗帕博利珠單抗(可瑞達®[2])一線治療PD-L1腫瘤比例分數(TPS)≥1%的EGFR基因突變陰性和ALK陰性的局部晚期或轉移性非小細胞肺癌(NSCLC)成人患者。本次受理是基於OptiTROP-Lung05註冊性III期研究的積極結果，該申請是蘆康沙妥珠單抗(sac-TMT)獲NMPA受理的第五項適應症上市申請。
More news about: 科倫博泰
May 08, 2026, 06:40 ET The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA
patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have PD-L1 tumor proportion score (TPS) ≥1% and are EGFR-negative and ALK-negative. This acceptance is based on the positive results from the OptiTROP-Lung05 registrational Phase III study, and the application is the
More news about: Kelun-Biotech
May 08, 2026, 06:35 ET Knight Therapeutics anuncia a aprovação regulatória do TAVALISSE® no Brasil
www.tavalisse.com/downloads/pdf/Tavalisse-Full-Prescribing-Information.pdf.3) National Heart, Lung, and Blood Institute. Immune Thrombocytopenia. U.S. Department of Health and Human Services,
More news about: Knight Therapeutics Inc.
May 08, 2026, 06:35 ET Knight Therapeutics anuncia la aprobación regulatoria de TAVALISSE® en Brasil
www.tavalisse.com/downloads/pdf/Tavalisse-Full-Prescribing-Information.pdf.3) National Heart, Lung, and Blood Institute. Immune Thrombocytopenia. U.S. Department of Health and Human Services,
More news about: Knight Therapeutics Inc.
May 07, 2026, 20:30 ET Chance Pharma Announces NMPA Acceptance of New Drug Application for Investigational Respiratory Drug CXG87
non-inferiority after 42 days of treatment, compared to the active control, Symbicort® Turbuhaler®. Patients achieved clear improvements in lung function, and favorable trends were observed in both asthma symptom relief and reduction in the frequency of asthma exacerbations. The overall safety
More news about: Chance Pharmaceuticals
May 07, 2026, 15:56 ET Try Gundry MD Dark Spot Diminisher To Help Helps Address The Appearance Of Age Spots, Sun Spots, And Liver Spots For Sun Awareness Week
cardiothoracic surgeons before leaving his practice to pursue restorative medicine. Today, he is the founder and medical director of The International Heart and Lung Institute and The Centers for Restorative Medicine in Palm Springs and Montecito, California, where he has spent the past 25 years helping people restore
More news about: Gundry MD
May 07, 2026, 14:06 ET West-MEC Celebrates Workforce-Ready Graduates Signing Career Commitments
ModigentSanderson FordWilson ElectricPurrfurred Pets Veterinary ClinicShock TherapyThe Dry BarAZ LungSurprise ToyotaThese placements reflect the variety of opportunities available to West-MEC graduates while reinforcing partnerships
More news about: West-MEC
May 07, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP
Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." According
More news about: Pomerantz LLP
May 07, 2026, 09:43 ET Tampa General Hospital Celebrates 15,000 Transplants Completed in Just Under Five Decades
the nation's elite centers for both volume and patient outcomes.Tampa General surpasses national averages in one-year survival outcomes across lung, heart, liver and kidney transplants, as ranked by the Scientific Registry of Transplant Recipients (SRTR)."This milestone is ultimately about
More news about: Tampa General Hospital
May 07, 2026, 08:00 ET Eko Health Appoints Dr. Steven Steinhubl as Chief Medical Officer
May 7, 2026 /PRNewswire/ -- Eko Health, a leader in applying artificial intelligence (AI) for the early detection of heart and lung diseases, today announced the appointment of Steven R. Steinhubl, MD, as Chief Medical Officer (CMO) and member of the executive leadership team.
More news about: Eko Health
May 07, 2026, 08:00 ET Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
dose-escalation trials for HWK-007 and HWK-016. HWK‑007 is being evaluated in patients with non-squamous, EGFR wild-type non-small cell lung cancer; platinum-resistant ovarian cancer; and endometrial cancer (NCT07444814).HWK‑016 is being evaluated in patients with advanced ovarian
More news about: Whitehawk Therapeutics, Inc.
May 07, 2026, 08:00 ET Pierre Fabre Pharmaceuticals Announces Regulatory Update Following Type A Meeting with U.S. Food and Drug Administration (FDA) on Tabelecleucel Biologic License Application (BLA)
therapies in development for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), NRAS-mutant melanoma, non-small cell lung cancer with mutation or amplification of MET, and X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED). Pierre Fabre Pharmaceuticals is headquartered
More news about: Pierre Fabre Pharmaceuticals
May 07, 2026, 07:00 ET Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
complex (MAC) lung disease, which met its primary and all multiplicity-controlled secondary culture conversion endpoints.Insmed plans to submit a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for ARIKAYCE in all patients with MAC lung disease in the
More news about: Insmed Incorporated
May 07, 2026, 07:00 ET TORL BioTherapeutics Appoints Aran Maree, M.D., as Chief Executive Officer and Evolves Leadership for Next Phase of Growth
Overexpression of CLDN6 occurs in specific malignancies and has been implicated in the pathogenesis of certain cancers including ovarian, non-small cell lung, endometrial and testicular malignancies. High expression correlates with shortened survival outcomes for patients with ovarian cancer.About
More news about: TORL Biotherapeutics LLC
May 07, 2026, 06:30 ET Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results
by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least 1 prior ROS1 tyrosine kinase inhibitor (TKI) with a Prescription Drug User Fee Act (PDUFA) target action date of
More news about: Nuvalent, Inc.
May 06, 2026, 16:30 ET Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis
awareness and proper diagnosis of bronchiectasis, a serious and chronic lung disease that may worsen over time and lead to lung damage. It encourages people with unresolved respiratory symptoms – such as cough, excess mucus, and recurrent lung infections, which may overlap with other respiratory conditions like
More news about: Insmed Incorporated
May 06, 2026, 16:26 ET IMMP Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Immutep Limited
The company's product pipeline includes TACTI-004, which is in phase III clinical trial evaluating eftilagimod alfa (efti) in patients with advanced lung cancer.
More news about: Robbins LLP
May 06, 2026, 12:42 ET Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1
and expanding adoption of testing recommendations in clinical practice guidelines, so that Alpha-1 detection becomes routine for patients impacted by lung and liver disease. The organization is increasing the availability of Alpha-1 detection tools and support at the practice level while partnering with
More news about: Alpha-1 Foundation
May 06, 2026, 09:29 ET Partner Therapeutics Announces Receipt of FDA Commissioner's National Priority Voucher for BIZENGRI® (Zenocutuzumab-zbco) in NRG1 Fusion-Positive Cholangiocarcinoma
for Grade 4 or life-threatening IRR or hypersensitivity/anaphylaxis reactions.Interstitial Lung Disease/Pneumonitis BIZENGRI can cause serious and life-threatening interstitial lung disease (ILD)/pneumonitis. In the eNRGy study, ILD/pneumonitis occurred in 2 (1.1%) patients
More news about: Partner Therapeutics, Inc.